High-dose opioids in advanced cancer: use factors-retrospective study.
[OBJECTIVES] To evaluate factors associated with high-dose opioid use in patients with advanced cancer and examine the effect of high-dose opioid use on patients' survival.
- p-value p=0.037
- p-value p=0.000
- 95% CI 1.054 to 5.792
APA
Peng W, Huang X, et al. (2025). High-dose opioids in advanced cancer: use factors-retrospective study.. BMJ supportive & palliative care, 16(1), 207-210. https://doi.org/10.1136/spcare-2024-005104
MLA
Peng W, et al.. "High-dose opioids in advanced cancer: use factors-retrospective study.." BMJ supportive & palliative care, vol. 16, no. 1, 2025, pp. 207-210.
PMID
39461883
Abstract
[OBJECTIVES] To evaluate factors associated with high-dose opioid use in patients with advanced cancer and examine the effect of high-dose opioid use on patients' survival.
[METHODS] This study retrospectively searched the medical records of 416 patients with advanced cancer in a home-based hospice in central China. Age, sex, type of cancer, type of pain, the maximum oral morphine equivalent daily dose, type of opioid, preadmission oral morphine equivalent daily dose, lung cancer or not, bone metastases, opioid switch and survival time were assessed.
[RESULTS] There were 416 subjects included from the 455 eligible participants (91.4%). 80 patients (19.2%) received high-dose opioids at home. Male (OR 2.471; 95% CI 1.054 to 5.792; p=0.037), preadmission morphine equivalent daily dose (OR 1.022; 95% CI 1.016 to 1.028; p=0.000) and the use of morphine at maximum morphine equivalent daily dose (OR 5.123; 95% CI 1.249 to 21.014; p=0.023) were positively predicted high-dose opioid use. No difference in survival was found when comparing the high-dose and very high-dose opioid use groups.
[CONCLUSIONS] Male home-based patients with advanced cancer who use morphine and have greater preadmission opioid doses should be aware of the necessity for high-dose opioid use. Regulated opioid use in adequate amounts does not shorten survival.
[METHODS] This study retrospectively searched the medical records of 416 patients with advanced cancer in a home-based hospice in central China. Age, sex, type of cancer, type of pain, the maximum oral morphine equivalent daily dose, type of opioid, preadmission oral morphine equivalent daily dose, lung cancer or not, bone metastases, opioid switch and survival time were assessed.
[RESULTS] There were 416 subjects included from the 455 eligible participants (91.4%). 80 patients (19.2%) received high-dose opioids at home. Male (OR 2.471; 95% CI 1.054 to 5.792; p=0.037), preadmission morphine equivalent daily dose (OR 1.022; 95% CI 1.016 to 1.028; p=0.000) and the use of morphine at maximum morphine equivalent daily dose (OR 5.123; 95% CI 1.249 to 21.014; p=0.023) were positively predicted high-dose opioid use. No difference in survival was found when comparing the high-dose and very high-dose opioid use groups.
[CONCLUSIONS] Male home-based patients with advanced cancer who use morphine and have greater preadmission opioid doses should be aware of the necessity for high-dose opioid use. Regulated opioid use in adequate amounts does not shorten survival.
MeSH Terms
Humans; Male; Female; Retrospective Studies; Analgesics, Opioid; Middle Aged; Aged; Cancer Pain; Neoplasms; China; Morphine; Aged, 80 and over; Adult
같은 제1저자의 인용 많은 논문 (5)
- Acquired L858R mutation following -TKI resistance in lung adenocarcinoma: a case report.
- ALKBH5-mediated m6A demethylation of TXNDC5 drives malignant progression in gastric cancer.
- Gut Microbiota and Chemotherapy-Induced Gastrointestinal Toxicity: Mechanisms and Intervention Strategies.
- Summary of best evidence for nutritional and dietary interventions in managing chemotherapy-induced gastrointestinal toxicity in cancer patients.
- How death reminders influence breast self-examination: testing the terror management health model among Chinese women.